Pediatric Clinics of North America - CIPERJ

THALASSEMIA UPDATE
459
[31] Kan YW, Allen A, Lowenstein L. Hydrops fetalis with alpha thalassemia. N Engl J Med
1967;276(1):18–23.
[32] Ehlers KH, Giardina PJ, Lesser ML, et al. Prolonged survival in patients with beta-thalassemia
major treated with deferoxamine. J Pediatr 1991;118(4 Pt 1):540–5.
[33] Karagiorga-Lagana M. Fertility in thalassemia: the Greek experience. J Pediatr Endocrinol
Metab 1998;11(Suppl 3):945–51.
[34] Skordis N, Petrikkos L, Toumba M, et al. Update on fertility in thalassaemia major. Pediatr
Endocrinol Rev 2004;2(Suppl 2):296–302.
[35] Skordis N, Christou S, Koliou M, et al. Fertility in female patients with thalassemia.
J Pediatr Endocrinol Metab 1998;11(Suppl 3):935–43.
[36] Pafumi C, Farina M, Pernicone G, et al. At term pregnancies in transfusion-dependent betathalassemic
women. Clin Exp Obstet Gynecol 2000;27(3–4):185–7.
[37] Hmida S, Mojaat N, Maamar M, et al. Red cell alloantibodies in patients with haemoglobinopathies.
Nouv Rev Fr Hematol 1994;36(5):363–6.
[38] Olujohungbe A, Hambleton I, Stephens L, et al. Red cell antibodies in patients with homozygous
sickle cell disease: a comparison of patients in Jamaica and the United Kingdom.
Br J Haematol 2001;113(3):661–5.
[39] Economidou J, Constantoulakis M, Augoustaki O, et al. Frequency of antibodies to various
antigenic determinants in polytransfused patients with homozygous thalassaemia in Greece.
Vox Sang 1971;20(3):252–8.
[40] Wang LY, Liang DC, Liu HC, et al. Alloimmunization among patients with transfusion-dependent
thalassemia in Taiwan. Transfus Med 2006;16(3):200–3.
[41] Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and
transfusion of racially unmatched blood. N Engl J Med 1990;322(23):1617–21.
[42] Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization
in transfusion-dependent thalassemia patients of predominantly asian descent. Blood 2000;
96(10):3369–73.
[43] Moroni GA, Piacentini G, Terzoli S, et al. Hepatitis B or non-A, non-B virus infection in
multitransfused thalassaemic patients. Arch Dis Child 1984;59(12):1127–30.
[44] Allain JP, Thomas I, Sauleda S. Nucleic acid testing for emerging viral infections. Transfus
Med 2002;12(4):275–83.
[45] O’Brien SF, Yi QL, Fan W, et al. Current incidence and estimated residual risk of transfusion-transmitted
infections in donations made to Canadian Blood Services. Transfusion
2007;47(2):316–25.
[46] Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and
haemodialysis patients in north Iran-Rasht. J Viral Hepat 2002;9(5):390–2.
[47] Butensky E, Pakbaz Z, Foote D, et al. Treatment of hepatitis C virus infection in thalassemia.
Ann N Y Acad Sci 2005;1054:290–9.
[48] Inati A, Taher A, Ghorra S, et al. Efficacy and tolerability of peginterferon alpha-2a with
or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection.
Br J Haematol 2005;130(4):644–6.
[49] Telfer PT, Garson JA, Whitby K, et al. Combination therapy with interferon alpha and ribavirin
for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol 1997;
98(4):850–5.
[50] Wonke B, Hoffbrand AV, Bouloux P, et al. New approaches to the management of
hepatitis and endocrine disorders in Cooley’s anemia. Ann N Y Acad Sci 1998;850:
232–41.
[51] Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia
syndromes. Br J Haematol 2004;124(1):114–7.
[52] Ren FY, Piao XX, Jin AL. Efficacy of ultrasonography and alpha-fetoprotein on early detection
of hepatocellular carcinoma. World J Gastroenterol 2006;12(29):4656–9.
[53] Borgna PC, Carnelli V, Caruso V, et al. Thromboembolic events in beta thalassemia major:
an Italian multicenter study. Acta Haematol 1998;99(2):76–9.